vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and CANTALOUPE, INC. (CTLP). Click either name above to swap in a different company.

CANTALOUPE, INC. is the larger business by last-quarter revenue ($78.7M vs $45.1M, roughly 1.7× Amarin Corp plc). CANTALOUPE, INC. runs the higher net margin — -0.1% vs -23.3%, a 23.2% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs 6.8%). Over the past eight quarters, CANTALOUPE, INC.'s revenue compounded faster (7.7% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Cantaloupe, Inc., previously known as USA Technologies Inc., is an American company known for its work with ePort cashless acceptance technology running on its patented ePort Connect service, a PCI compliant services. ePort Connect wirelessly facilitates electronic payment options to consumers with credit, debit, or NFC enabled electronic wallets like Apple Pay and Google Pay while providing operators with both telemetry and machine-to-machine (M2M) services. ePort technology is primarily fou...

AMRN vs CTLP — Head-to-Head

Bigger by revenue
CTLP
CTLP
1.7× larger
CTLP
$78.7M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+0.2% gap
AMRN
7.0%
6.8%
CTLP
Higher net margin
CTLP
CTLP
23.2% more per $
CTLP
-0.1%
-23.3%
AMRN
Faster 2-yr revenue CAGR
CTLP
CTLP
Annualised
CTLP
7.7%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
AMRN
AMRN
CTLP
CTLP
Revenue
$45.1M
$78.7M
Net Profit
$-10.5M
$-70.0K
Gross Margin
Operating Margin
2.0%
Net Margin
-23.3%
-0.1%
Revenue YoY
7.0%
6.8%
Net Profit YoY
33.0%
-101.4%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
CTLP
CTLP
Q1 26
$45.1M
Q4 25
$49.2M
$78.7M
Q3 25
$49.7M
$80.9M
Q2 25
$72.7M
$82.6M
Q1 25
$42.0M
$75.4M
Q4 24
$62.3M
$73.7M
Q3 24
$42.3M
$70.8M
Q2 24
$67.5M
$72.7M
Net Profit
AMRN
AMRN
CTLP
CTLP
Q1 26
$-10.5M
Q4 25
$-1.2M
$-70.0K
Q3 25
$-7.7M
$-919.0K
Q2 25
$-14.1M
$6.8M
Q1 25
$-15.7M
$49.2M
Q4 24
$-48.6M
$5.0M
Q3 24
$-25.1M
$3.6M
Q2 24
$1.5M
$2.2M
Gross Margin
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
-12.9%
2.0%
Q3 25
-22.4%
2.0%
Q2 25
-22.0%
6.3%
Q1 25
-39.9%
9.1%
Q4 24
-84.3%
8.4%
Q3 24
-59.5%
5.8%
Q2 24
-0.8%
4.9%
Net Margin
AMRN
AMRN
CTLP
CTLP
Q1 26
-23.3%
Q4 25
-2.5%
-0.1%
Q3 25
-15.6%
-1.1%
Q2 25
-19.4%
8.3%
Q1 25
-37.4%
65.2%
Q4 24
-78.0%
6.7%
Q3 24
-59.4%
5.0%
Q2 24
2.3%
3.0%
EPS (diluted)
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
$0.00
$0.00
Q3 25
$-0.02
$-0.02
Q2 25
$-0.03
$0.10
Q1 25
$-0.04
$0.65
Q4 24
$-0.12
$0.07
Q3 24
$-0.06
$0.04
Q2 24
$0.00
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
CTLP
CTLP
Cash + ST InvestmentsLiquidity on hand
$307.8M
$53.0M
Total DebtLower is stronger
$37.7M
Stockholders' EquityBook value
$252.5M
Total Assets
$645.8M
$381.9M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
CTLP
CTLP
Q1 26
$307.8M
Q4 25
$302.6M
$53.0M
Q3 25
$286.6M
$55.0M
Q2 25
$298.7M
$51.1M
Q1 25
$281.8M
$46.3M
Q4 24
$294.2M
$27.7M
Q3 24
$305.7M
$33.1M
Q2 24
$306.7M
$58.9M
Total Debt
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
$37.7M
Q3 25
$38.3M
Q2 25
$38.7M
Q1 25
$39.2M
Q4 24
$37.0M
Q3 24
$37.3M
Q2 24
$37.5M
Stockholders' Equity
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
$459.3M
$252.5M
Q3 25
$458.9M
$251.8M
Q2 25
$464.9M
$251.0M
Q1 25
$473.7M
$240.7M
Q4 24
$486.2M
$190.1M
Q3 24
$531.4M
$186.2M
Q2 24
$551.9M
$181.7M
Total Assets
AMRN
AMRN
CTLP
CTLP
Q1 26
$645.8M
Q4 25
$670.8M
$381.9M
Q3 25
$659.8M
$389.5M
Q2 25
$670.1M
$381.9M
Q1 25
$655.7M
$370.5M
Q4 24
$685.3M
$303.0M
Q3 24
$750.6M
$312.1M
Q2 24
$799.9M
$335.6M
Debt / Equity
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.15×
Q1 25
0.16×
Q4 24
0.19×
Q3 24
0.20×
Q2 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
CTLP
CTLP
Operating Cash FlowLast quarter
$3.1M
Free Cash FlowOCF − Capex
$-614.0K
FCF MarginFCF / Revenue
-0.8%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$25.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
$15.3M
$3.1M
Q3 25
$-12.7M
$7.0M
Q2 25
$16.6M
$9.4M
Q1 25
$-12.5M
$22.4M
Q4 24
$-13.3M
$522.0K
Q3 24
$-2.4M
$-12.0M
Q2 24
$-2.7M
$14.3M
Free Cash Flow
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
$-614.0K
Q3 25
$3.5M
Q2 25
$4.3M
Q1 25
$18.6M
Q4 24
$-3.8M
Q3 24
$-15.8M
Q2 24
$8.5M
FCF Margin
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
-0.8%
Q3 25
4.4%
Q2 25
5.3%
Q1 25
24.6%
Q4 24
-5.1%
Q3 24
-22.3%
Q2 24
11.7%
Capex Intensity
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
4.8%
Q3 25
4.2%
Q2 25
6.2%
Q1 25
5.1%
Q4 24
5.8%
Q3 24
5.4%
Q2 24
7.9%
Cash Conversion
AMRN
AMRN
CTLP
CTLP
Q1 26
Q4 25
Q3 25
Q2 25
1.38×
Q1 25
0.46×
Q4 24
0.10×
Q3 24
-3.36×
Q2 24
-1.81×
6.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

CTLP
CTLP

Transaction Processing$47.9M61%
Subscription Revenue$21.8M28%
Products$9.0M11%

Related Comparisons